Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE | stella

Learn Data Labs For Researchers Find trials matched to me

Learn Data Labs For Researchers Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE | stella

Back to Systemic Lupus Erythematosus trials

Recruiting

Plain-English translation of NCT07318259 on ClinicalTrials.gov ↗ · Source last updated February 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(1 site)

China

Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu

Key details

Phase

Safety & dosing

Sponsor

Chongqing Precision Biotech Co., Ltd

Enrollment target

~18 participants

Started

January 2026

Primary completion

July 2026

Age range

18 Years and older

Last updated on clinicaltrials.gov in February 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Lingyun Sun

Chongqing Precision Biotech Co., Ltd

View full record on ClinicalTrials.gov

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.